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Cutting Edge: Circulating Plasmablasts Induce the
Differentiation of Human T Follicular Helper Cells via
IL-6 Production
Konstantia-Maria Chavele, Eve Merry, and Michael R. Ehrenstein
B cells require CD4+ T follicular helper (Tfh) cells to
progress through the germinal center and provide
protective Ab responses. In this article, we reveal a
reciprocal interaction whereby circulating human plas-
mablasts are potent inducers of the Tfh cell–differ-
entiation program, including the expression of their
key transcription factor Bcl-6. The markedly increased
propensity of plasmablasts, compared with naive
B cells, to induce Tfh cell differentiation was due to
their increased production of IL-6. Specific targeting of
IL-6 using tocilizumab therapy in patients with rheu-
matoid arthritis led to a significant reduction in circu-
lating Tfh cell numbers and IL-21 production, which
was correlated with reduced plasmablast formation.
Our data uncover a positive-feedback loop between
circulating plasmablasts and Tfh cells that could sus-
tain autoimmunity and spread Ab-driven inflammation
to unaffected sites; this represents an important thera-
peutic target, as well as reveals a novel mechanism of
action for tocilizumab. The Journal of Immunology,
2015, 194: 2482–2485.
C
D4+ T follicular helper (Tfh) cells are a specialized
Th subset that provides signals to B cells and guides
their development through the germinal center (GC)
(1). This Tfh cell–B cell interaction lies at the heart of the GC
and is key for efficient immune responses; however, it also
can promote autoimmune disease. Tfh cells express the tran-
scriptional repressor Bcl-6; produce IL-21, which is essential
for robust high-affinity humoral responses; and express ICOS
and CXCR5, the latter directing this cell lineage to the GC.
B cells with the highest affinity for Ag present cognate pep-
tides to Tfh cells and, in turn, receive critical signals allowing
their survival and differentiation into memory B cells and
plasma cells. The differentiation of Tfh cells is reliant upon
multiple signals, including cytokines, such as IL-6 and IL-21
(2, 3). Murine B cells can reciprocally modulate Tfh cell
dynamics and promote their formation, such as by the pro-
vision of IL-6. In contrast, little is known about the role of
B cells in human Tfh cell differentiation. In this article, we
investigate the role of B cells in the induction of human Tfh
cells.
Materials and Methods
Healthy individuals and patients
Blood was obtained from healthy individual volunteers and patients with rheu-
matoid arthritis (RA) before and 6 mo after treatment with tocilizumab. The mean
disease activity score (DAS28) in the paired samples before and after tocilizumab
treatment was 7.2 and 3.5, respectively. These patients were not taking any other
disease-modifying antirheumatic drugs and were on ,7.5 mg prednisolone/d.
The University College London Hospital ethics committee approved the study.
The n values in the figure legends refer to independent donors.
Human cell isolation
B cells were depleted from PBMCs by positive selection with magnetic
beads (Miltenyi Biotec). Responder and naive T cells were sorted as
CD4+CD252CD127+ and CD4+CD45RA+CD27+, respectively. B cell sub-
populations, including plasmablasts and naive and memory B cells, were
sorted as CD19+CD38+CD27+, CD19+IgD+CD382/intCD272, and
CD19+CD382CD27+ respectively.
Cell culture
PBMCs were stimulated with 2 mg/ml soluble anti-CD3 (HIT3a) and anti-
CD28 (CD28.2) (eBioscience). A total of 50,000 cells each was used for
cocultures of T and B cells. For Tfh functional assays, CD4+ T cells were
resorted after 4 d of culture, with or without plasmablasts, and cultured with
autologous freshly sorted naive B cells in the presence of 2 mg/ml endotoxin-
reduced Staphylococcal enterotoxin B (Sigma-Aldrich). Naive T cells were
cultured with 10 ng/ml of IL-21 or IL-6 or a combination of both (Pepro-
Tech).
Abs
The following Abs were used: CD4–Alexa Fluor 700, CXCR5-Biotin, ICOS-
PECy7, Bcl-6–Alexa Fluor 647, CD27–allophycocyanin–H7, CD45RA-PE,
CD19-allophycocyanin or V450, IgD-FITC, IL-21–Alexa Fluor 647, IFN-g–
PECy7, IL-10–PE, Streptavidin–PE–Texas Red (BD Biosciences), CD38–
PerCP–eFluor 710, and IL-6–FITC (BioLegend). Neutralizing Abs specific
for human IL-6 and IL-21R and isotype controls were from R&D Systems.
Flow cytometry
For analysis of intracellular cytokines, cells were stimulated for 4 h with 50 ng/
ml PMA, 250 ng/ml ionomycin (Sigma-Aldrich), and GolgiPlug (BD Bio-
sciences). Data were acquired on an LSR II (Becton Dickinson) and analyzed
with FlowJo software (TreeStar).
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ELISA
IL-6 (eBioscience) and Ig (IgMand IgG) production (Sigma-Aldrich) wasmeasured
in supernatants by ELISA, according to the manufacturers’ instructions.
Statistical analysis
Data were analyzed for significance by the paired t test using Prism (GraphPad,
La Jolla, CA). The Mann–Whitney U test was used to compare healthy
individuals and patients with RA. Correlation coefficients and their signifi-
cance were analyzed by the Pearson correlation.
Results and Discussion
Plasmablasts promote Tfh cell expansion
Human Tfh cells coexpress CXCR5 and ICOS at high density
(4). In our study, Tfh cells were defined as CD4+CXCR5+I-
COS+. Only a small fraction of circulating CD4+ T cells in
healthy donors possessed these characteristics (Fig. 1A), as
well as expressed PD1 but were negative for CD45RA
(Supplemental Fig. 1A). Bcl-6 was expressed at low levels in
FIGURE 1. B cells promote human Bcl-6+ Tfh cells. PBMCs from healthy individuals (n = 8) were stained for Tfh cell markers CXCR5 and ICOS. B cell–
depleted and whole PBMCs were stimulated with anti-CD3/CD28 for 3 d and stained for Tfh cell markers (n = 8). (A) Representative flow cytometry plots
(gated on CD4) and cumulative data (mean6 SE) showing the frequency of Tfh cells. (B) Representative graphs and cumulative data (mean6 SE) showing Bcl-
6 expression in Tfh cells (mean fluorescence intensity and % Bcl-6+ gated on CXCR5+ICOS+ T cells). (C) Purified Tresp cells from healthy individuals were
stimulated or not with autologous B cells for 4 d with anti-CD3 and IL-4. Representative flow cytometry plots and cumulative data showing the percentage of Tfh
cells (n = 12, mean 6 SE). (D) Representative graphs of Bcl-6 expression in Tfh cells from cultures described in (C). (E) Correlation between the percentage of
Tfh cells and plasmablasts from cultures described in (C). (F) Responder T cells from healthy individuals were cultured alone or with naive B cells or plasmablasts
for 4 d, and the percentage of Tfh cells was determined (n = 5, mean 6 SE). *p , 0.05, **p , 0.01, ***p , 0.001.
FIGURE 2. Plasmablasts induce the differentiation of Tfh cells. Naive T cells together with naive B cells, memory B cells, plasmablasts, or monocytes were
stimulated with anti-CD3/CD28 for 4 d. (A) Representative flow cytometry plots (gated on CD4+ T cells) and cumulative data showing the percentage of Tfh
cells (n = 35, mean 6 SE). (B) Representative graphs showing Bcl-6 expression in Tfh cells induced in the presence of plasmablasts; mean fluorescence intensity
value is indicated. (C) Representative flow cytometry plots and cumulative data showing the percentage of Tfh cells expressing IL-21 in cultures of naive T cells
with naive B cells or plasmablasts (n = 9, mean6 SE). CD4+ T cells were repurified from cultures of naive T cells alone (TfhNT) or with plasmablasts (TfhPL) (day
4) and cocultured with freshly isolated autologous naive (D) or memory (E) B cells in the presence of Staphylococcal enterotoxin B for 10 d. IgM and IgG Ab
production was measured by ELISA (n = 5, mean 6 SE). **p , 0.001, ***p , 0.0001.
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circulating Tfh cells (Fig. 1B), consistent with previous
findings (4). In contrast, when PBMCs were stimulated with
anti-CD3/CD28, CXCR5 and ICOS expression greatly in-
creased (Fig. 1A), as did Bcl-6 expression in Tfh cells (Fig.
1B). We sought to identify whether B cells promoted the
formation of Tfh cells and found that removal of the former
from PBMCs led to a significant reduction in Tfh cells (Fig.
1A), as well as Bcl-6 expression in the Tfh cell population,
after stimulation with anti-CD3/CD28 (Fig. 1B), suggesting
a role for B cells in the maintenance of this T cell lineage.
This finding prompted us to address whether B cells directly
support the expansion of Tfh cells. Responder T (Tresp) cells
(CD4+CD252CD127+) were cultured with CD19+ B cells
and stimulated with either anti-CD3 and IL-4 (Fig. 1C) or
anti-CD3/CD28 (Supplemental Fig. 1B). The percentage of
Tfh cells increased significantly in the presence of B cells
under both conditions. These Tfh cells expressed high levels
of Bcl-6 (Fig. 1D), as well as PD-1, CD200, and CD57
(data not shown). In these cocultures, the percentage of
Tfh cells correlated with the percentage of plasmablasts
(CD19+CD38highCD27high) (Fig. 1E) but not naive B cells
(CD19+IgD+CD382/lowCD272) or memory B cells (CD19+
CD382CD27+) (Supplemental Fig. 1C).
Given the close correlation between plasmablasts and Tfh
cells, we hypothesized that this B cell subset was responsible for
the increased frequency of Tfh cells. Therefore, plasmablasts
were isolated from peripheral blood, according to their ex-
pression of CD38 and CD27 (5) (Supplemental Fig. 1D), and
compared with naive B cells for their ability to expand Tfh
cells. Plasmablasts, but not naive B cells, could drive the ex-
pansion of Tfh cells from Tresp cells (Fig. 1F). Our data
reveal that not all circulating B cells are equally equipped to
expand Tfh cells and identify the potent properties of plas-
mablasts in increasing Tfh cell numbers.
Plasmablasts induce the differentiation of Tfh cells
We next assessed whether circulating plasmablasts possessed
the capacity to induce the differentiation of Tfh cells from
naive T cells. Thus, plasmablasts, naive and memory B cells,
and monocytes were isolated and added to naive T cells in the
presence of anti-CD3/CD28. Plasmablasts were the most
potent inducers of Tfh cell differentiation (Fig. 2A). Tfh cells
induced in the presence of plasmablasts expressed high levels
of PD-1 (Supplemental Fig. 1E) and Bcl-6 (Fig. 2B). In ad-
dition, plasmablast-induced Tfh cells secreted significantly
more IL-21 compared with naive B cell–induced Tfh cells
(Fig. 2C). Although naive B cells possessed some ability to
induce Tfh cell differentiation, this could be explained, in
part, by the formation of plasmablasts from naive B cells
during the culture (Supplemental Fig. 1F). Indeed, the per-
FIGURE 3. Plasmablast production of IL-6 induces Tfh cell differentiation. (A) Plasmablasts and naive and memory B cells from healthy PBMCs were stained
for intracellular production of IL-6. Frequency of IL-6–secreting cells is shown (n = 9, mean 6 SE). (B) IL-6 levels in supernatants collected 4 d after culture of
naive T cells either alone or with naive B cells or plasmablasts stimulated with anti-CD3/CD28 (n = 9, mean 6 SE). (C) Naive T cells from healthy individuals
(n = 8) were stimulated with anti-CD3/CD28 for 6 d in the presence or absence of 10 ng/ml IL-21, IL-6, or a combination (cumulative data showing mean 6
SE). (D) Addition of anti–IL-21R (aIL-21R) and/or anti–IL-6 (aIL-6) in cultures of naive T cells and plasmablasts or naive T cells and naive B cells (n = 11,
mean 6 SE). (E) In vitro cocultures of naive T cells and plasmablasts were treated with anti–IL-6–blocking Ab for 4 d, and CD4+ T cells were stained for IL-21
(n = 8). (F) Representative flow cytometry plots gated on CD4+ T cells showing the frequency of Tfh cells pre- and posttocilizumab therapy. (G) PBMCs from 41
healthy individuals and 6 paired patients with RA (pre- and posttocilizumab therapy) were stained ex vivo for Tfh cells. Cumulative data presented in a scatter dot
plot showing mean percentage of Tfh cells in the CD4 compartment. (H) Cumulative data showing percentage of IL-21–producing CD4+ T cells. PBMCs from
32 healthy individuals and 6 paired RA patients (pre- and posttocilizumab therapy) were stained ex vivo for plasmablasts. (I) Representative flow cytometry plots
showing the frequency of plasmablasts (percentages of CD27highCD38high are indicated) pre- and posttocilizumab therapy. (J) Cumulative data showing mean
percentage of plasmablasts. (K) The percentage of Tfh cells was correlated with the percentage of plasmablasts in RA patients receiving tocilizumab treatment
(n = 22). *p , 0.05, **p , 0.01, ***p , 0.001.
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centage of Tfh cells correlated with the numbers of plasma-
blasts present in these “naive B cell” cultures (Supplemental
Fig. 1G). This finding suggests that the induction of Tfh cell
differentiation was due, in part, to newly formed plasmablasts
from naive B cells, although other mechanisms may con-
tribute, given that monocytes can increase the number of Tfh
cells above that seen with naive T cells alone. To support this
finding we cocultured different ratios of naive CD4+ T cells/
plasmablasts and assessed the induction of Tfh cell differen-
tiation. The ratio of plasmablasts/naive CD4+ T cells in these
cultures was directly proportional to Tfh cell differentiation
(Supplemental Fig. 1H). To ascertain whether the differen-
tiated Tfh cells were functional, T cells were repurified after
4 d of culture with plasmablasts and incubated with freshly
isolated autologous naive B cells or memory B cells, as pre-
viously described (6). Plasmablast-induced Tfh cells provided
enhanced B cell help and supported naive B cells and memory
B cells to produce significantly more IgM (Fig. 2D) and IgG
(Fig. 2E), respectively, compared with T cells that had not
been exposed to plasmablasts. To our knowledge, our results
show for the first time that human plasmablasts are potent
inducers of Tfh cell differentiation. Of relevance, murine
plasma cells were shown to inhibit, rather than promote, Tfh
cell formation (7). This discrepancy may reflect differences be-
tween plasma cells and circulating plasmablasts, or it could be
due to differential regulation of Tfh cells in mice and humans.
Plasmablast-derived IL-6 induces Tfh cells
In our efforts to elucidate the mechanism by which plasmablasts
induce Tfh cell differentiation, we discovered that plasmablasts
produce large amounts of IL-6, more than either naive or memory
B cells (Fig. 3A, Supplemental Fig. 2A). Plasmablasts cultured
with naive T cells yielded more IL-6 than did naive B cells and
T cells or naive T cells alone (Fig. 3B). In addition, IL-6 detected
in the coculture supernatants correlated with the percentage of Tfh
cells (Supplemental Fig. 2B). Addition of IL-21 and IL-6 to naive
T cells significantly induced Tfh cell differentiation (Fig. 3C,
Supplemental Fig. 2C). Tfh cell differentiation was greater when
a combination of IL-21 and IL-6 was used, confirming previous
observations in mice whereby loss of both IL-6 and IL-21 led to
a significant reduction in Tfh cell numbers (2, 3). Although IL-12
has been implicated in human Tfh cell differentiation (8), we
could not detect IL-12 production by plasmablasts.
We next investigated whether the production of IL-6 and IL-21
mediated the differentiation of Tfh cells by plasmablasts. In vitro
blockade of IL-21R or IL-6 in cocultures of naive T cells and
plasmablasts significantly decreased the acquisition of a Tfh cell
phenotype (Fig. 3D). Blockade of both cytokines further reduced
the percentage of Tfh cells to the level found when naive B cells
replaced plasmablasts in these cultures. Furthermore, IL-6 block-
ade in cultures of plasmablasts and naive T cells from healthy
individuals also reduced IL-21 production by T cells (Fig. 3E),
suggesting that IL-6 plays an important role in inducing Tfh cells
through the stimulation of T cell IL-21 production.
Tocilizumab therapy in patients with RA reduces Tfh cells and
plasmablasts
To glean some insight into the in vivo relevance of our findings
in patients, we investigated the interrelationships between Tfh
cells and plasmablasts in patients with RA before and after
tocilizumab therapy. Tocilizumab targets IL-6R and is an effective
treatment for patients with RA (9). In agreement with previous
studies (10), RA patients showed significantly more circulating
Tfh cells compared with healthy individuals (Figs. 1A, 3F, 3G).
Consistent with our in vitro data, RA patients responding
to tocilizumab therapy showed a marked reduction in circulat-
ing Tfh cells (Fig. 3G). Paralleling our in vivo observations,
CD4+ T cell IL-21 production was decreased significantly after
treatment with tocilizumab (Fig. 3H). Tocilizumab treatment
also reduced the plasmablast frequency in patients with RA
(Fig. 3I, 3J). Moreover, there was a significant correlation be-
tween the percentage of Tfh cells and plasmablasts in patients
with RA after tocilizumab treatment (Fig. 3K). These results
suggest that tocilizumab could ameliorate disease by reducing
Tfh cells and Ab-secreting cells in RA.
Our data implicate a previously unrecognized function of
human circulating plasmablasts as potent inducers of Tfh cell
differentiation via IL-6. One can envisage a feedback mechanism
by which circulating plasmablasts traffic from one inflammatory
site and create further foci of inflammation through the differ-
entiation of Tfh cells, which, in turn, induces plasmablast for-
mation. This feedback mechanism is tightly controlled under
normal conditions; however, in infections and autoimmune
diseases it could rapidly result in large numbers of Tfh cells and
plasmablasts in several locations. This amplification loop repre-
sents an important therapeutic target in autoimmune diseases,
such as RA, and it also could be boosted to improve responses to
infection and to enhance vaccination strategies.
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